Business
Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter
Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter\n \n \nEaston Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter\n \n TORONTO, ON--(Marketwired - Jan 4, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), along with its partners BMV Medica and its host Ackerman Pharma, announce receipt of initial purchase order for the Gynofit Lactic Acid Gel Treatment from Gedeon Richter for their product launch in Mexico slated for this February.\n As per its recently announced distribution agreement with Gedeon Richter, Easton / BMV and their host laboratory, Ackerman Pharma, have received an initial purchase order for their in-licensed Gynofit Lactic Acid Gel Treatment with delivery from Switzerland expected later this month, and subsequent delivery to Gedeon Richter in Mexico for an expected February product launch. This agreement coincides with its recent distribution agreement executed with Windsor Pharmaceuticals for Central America which is pending regulatory approval.\n \"This PO represents the beginning towards delivering sales in 2017 and beyond as we slowly initiate launching our products throughout the territories we have received approval in,\" stated Evan Karras, CEO of Easton Pharmaceuticals. Mr. Karras further commented, \"We expect sales to slowly grow and becoming very robust over the coming years as this natural treatment for Bacterial Vaginosis will be marketed as a natural alternative to antibiotics to successfully treat vaginal infections and also marketed to maintain optimal vaginal flora.\"\n \"Gynofit\" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its suc...